1. Home
  2. DCTH vs VALN Comparison

DCTH vs VALN Comparison

Compare DCTH & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DCTH
  • VALN
  • Stock Information
  • Founded
  • DCTH 1988
  • VALN 2012
  • Country
  • DCTH United States
  • VALN France
  • Employees
  • DCTH N/A
  • VALN N/A
  • Industry
  • DCTH Medical/Dental Instruments
  • VALN Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • DCTH Health Care
  • VALN Health Care
  • Exchange
  • DCTH Nasdaq
  • VALN Nasdaq
  • Market Cap
  • DCTH 630.4M
  • VALN 510.7M
  • IPO Year
  • DCTH N/A
  • VALN 2021
  • Fundamental
  • Price
  • DCTH $16.30
  • VALN $6.41
  • Analyst Decision
  • DCTH Strong Buy
  • VALN Strong Buy
  • Analyst Count
  • DCTH 4
  • VALN 3
  • Target Price
  • DCTH $24.00
  • VALN $15.33
  • AVG Volume (30 Days)
  • DCTH 610.5K
  • VALN 80.4K
  • Earning Date
  • DCTH 05-08-2025
  • VALN 05-07-2025
  • Dividend Yield
  • DCTH N/A
  • VALN N/A
  • EPS Growth
  • DCTH N/A
  • VALN N/A
  • EPS
  • DCTH N/A
  • VALN N/A
  • Revenue
  • DCTH $53,850,000.00
  • VALN $201,099,222.00
  • Revenue This Year
  • DCTH $141.47
  • VALN $18.74
  • Revenue Next Year
  • DCTH $49.31
  • VALN $29.26
  • P/E Ratio
  • DCTH N/A
  • VALN N/A
  • Revenue Growth
  • DCTH 1068.87
  • VALN 21.64
  • 52 Week Low
  • DCTH $6.33
  • VALN $3.62
  • 52 Week High
  • DCTH $18.23
  • VALN $9.50
  • Technical
  • Relative Strength Index (RSI)
  • DCTH 58.68
  • VALN 48.84
  • Support Level
  • DCTH $15.73
  • VALN $6.18
  • Resistance Level
  • DCTH $17.29
  • VALN $6.54
  • Average True Range (ATR)
  • DCTH 0.96
  • VALN 0.19
  • MACD
  • DCTH -0.08
  • VALN 0.02
  • Stochastic Oscillator
  • DCTH 50.58
  • VALN 56.61

About DCTH Delcath Systems Inc.

Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.

About VALN Valneva SE

Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.

Share on Social Networks: